A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

• Status: Active, not recruiting
• Trial end date: 2024-07-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants with Type 2 Diabetes (T2DM).

• Participants who are insulin naive or receiving basal insulin [NPH (neutral protamine Hagedorn) once or twice daily, once-daily insulin glargine U100 or U300, once-daily insulin degludec, or insulin detemir once or twice daily] for fewer than 5 years prior to screening.

• Have glycated hemoglobin (HbA1c) of ≥7.0 percent (%) to ≤9.5%, HbA1c of ≥6.5% to ≤9.5% for participants on treatment with sulfonylureas and/or Sodium-Glucose Transport Protein 2 inhibitors who require washout.

• Have a body mass index between 27 and 40 kilograms per meter square.

• Male or female participants who are willing to comply with the contraception requirements consistent with local regulations.

• Be willing to allow blood sample collection, reliable and to be available for the duration of the study as required for the study protocol.

Exclusion Criteria:

• Have known or suspected allergic reactions to study drugs, related compounds, excipients, and devices used in the study.

• Have a specific type of diabetes other than T2DM.

• Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.

• Participants with a history of kidney complications.